NASDAQ:MDCOThe Medicines Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.90 0.00 (0.00 %) (As of 01/6/2020) Add Compare Share Today's Range$84.90Now: $84.90▼$84.9050-Day Range$84.90MA: $84.90▼$84.9052-Week Range$17.81Now: $84.90▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/ABeta1.1 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingThe Medicines has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.75, The Medicines has a potential downside of 9.6% from its current price of $84.90.Amount of Analyst CoverageThe Medicines has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesThe Medicines has received 515 “outperform” votes. (Add your “outperform” vote.)Underperform VotesThe Medicines has received 384 “underperform” votes. (Add your “underperform” vote.)Community SentimentThe Medicines has received 57.29% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote “Outperform” if you believe MDCO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldThe Medicines does not currently pay a dividend.Dividend GrowthThe Medicines does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, The Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.41% of the stock of The Medicines is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for The Medicines are expected to decrease in the coming year, from ($3.42) to ($3.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of The Medicines is -29.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of The Medicines is -29.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MDCO Previous Symbol CUSIP58468810 CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Profitability EPS (Most Recent Fiscal Year)($2.91) Net Income$-123,160,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-25.70%Miscellaneous Employees62 Outstanding Shares79,723,000Market Cap$6.77 billion Next Earnings Date7/22/2020 (Estimated) OptionableOptionable Receive MDCO News and Ratings via Email Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter. The Medicines (NASDAQ:MDCO) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of The Medicines? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for The Medicines. When is The Medicines' next earnings date? The Medicines is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for The Medicines. How were The Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) announced its earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.12. During the same quarter in the prior year, the business earned ($0.70) earnings per share. View The Medicines' earnings history. What price target have analysts set for MDCO? 12 Wall Street analysts have issued twelve-month target prices for The Medicines' stock. Their forecasts range from $49.00 to $145.00. On average, they anticipate The Medicines' stock price to reach $76.75 in the next twelve months. This suggests that the stock has a possible downside of 9.6%. View analysts' price targets for The Medicines. Has The Medicines been receiving favorable news coverage? Press coverage about MDCO stock has trended very negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. The Medicines earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about The Medicines. Who are some of The Medicines' key competitors? Some companies that are related to The Medicines include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of The Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), salesforce.com (CRM), Bank of America (BAC), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Celgene (CELG). Who are The Medicines' key executives? The Medicines' management team includes the following people: Mr. Mark Timney, CEO & Director (Age 54)Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)Dr. Goutham Krishna Gorti, VP & Head of Investor Relations What is The Medicines' stock symbol? The Medicines trades on the NASDAQ under the ticker symbol "MDCO." What is The Medicines' stock price today? One share of MDCO stock can currently be purchased for approximately $84.90. How big of a company is The Medicines? The Medicines has a market capitalization of $6.77 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe. What is The Medicines' official website? The official website for The Medicines is www.themedicinescompany.com. How can I contact The Medicines? The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
